Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on R Lansoprazole. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel vanadium-catalyzed asymmetric oxidation for S-omeprazole. High purity, scalable process reducing costs for pharmaceutical supply chains globally.
Patent CN101012141B reveals catalytic oxidation for high-purity PPIs. Enables cost reduction in pharmaceutical intermediates manufacturing with scalable routes.
Patent CN104387368A details a novel enantioselective oxidation for R-Lansoprazole. Achieve 99.5% ee with reduced impurities and scalable manufacturing processes.
Novel patent CN106543146A offers efficient R-lansoprazole preparation. Enhances supply chain reliability and reduces manufacturing costs for global pharmaceutical partners.
Patent CN1214027C details a novel route for PPI intermediates using N-oxide activation, offering significant cost reduction in API manufacturing and improved supply chain reliability.
Patent CN102731478A details a high-yield asymmetric oxidation route for Dexlansoprazole intermediates, offering superior optical purity and scalable manufacturing solutions.
Patent CN105399728B reveals high-yield R-lansoprazole production. Enhances supply chain reliability and reduces manufacturing costs for pharmaceutical partners globally.
Novel catalytic oxidation process for S-omeprazole and analogs ensures high optical purity and simplified production workflow for global supply chains.
Patent CN106866630B reveals high-yield asymmetric oxidation for R-lansoprazole. Reduces impurities and enhances commercial scalability for pharmaceutical supply chains globally.
Novel enantioselective oxidation method using titanium-tartrate catalysts offers high purity and cost efficiency for proton pump inhibitor manufacturing.
Patent CN102977076A reveals a high-purity R-lansoprazole synthesis using chiral titanium catalysis. Discover cost-effective manufacturing insights for pharmaceutical supply chains.
Patent CN102558151A reveals a green asymmetric oxidation method for proton pump inhibitors, offering high enantioselectivity and reduced heavy metal contamination for reliable API intermediate suppliers.
Patent CN102225909B reveals a one-step synthesis for lansoprazole intermediates, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturers.
Patent CN102225909B reveals a one-step POCl3 method for 2-chloromethyl-3-methyl-4-trifluoroethoxypyridine, offering significant cost and efficiency advantages for API manufacturers.
Patent CN104177336A details efficient asymmetric oxidation for Dexlansoprazole. Achieve high optical purity and cost reduction in pharma manufacturing.
Patent CN1839127A details a cost-effective NaOCl oxidation process for PPIs like Pantoprazole, minimizing sulfone impurities and ensuring high purity for commercial scale-up.
Novel process for dexlansoprazole via trifluoroethanol substitution improves purity and scalability for API manufacturing supply chains.
Patent CN102603714B details a high-yield asymmetric oxidation method for PPI intermediates. Discover cost-effective manufacturing and supply chain advantages.
Patent CN101323609A details a novel asymmetric oxidation method for high-purity PPI intermediates, offering significant cost reduction and supply chain reliability.
Patent CN103694225A reveals a stable titanium catalyst ligand for high-yield dexlansoprazole synthesis, offering significant cost reduction and supply reliability for API manufacturing.